Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. reports news on its dermatology therapeutics business, including commercialization of YCANTH (VP-102) for molluscum contagiosum and development of cantharidin-based therapy for common warts. Company updates also cover financial results, corporate presentations, commercial leadership and international commercialization activity.
Verrica’s pipeline news centers on VP-315 (ruxotemitide), an oncolytic peptide licensed for dermatologic oncology indications. Recurring disclosures include clinical data presentations in basal cell carcinoma, development plans for non-melanoma skin cancers and collaboration activity tied to YCANTH and its dermatology portfolio.
Verrica Pharmaceuticals (NASDAQ: VRCA) announced a public offering of 2,033,899 shares at $14.75 each, aiming for gross proceeds of approximately $30 million. Underwriters have a 30-day option for an additional 305,084 shares. The offering is set to close around March 25, 2021, pending customary conditions. Jefferies, Cowen, and RBC Capital Markets are overseeing the offering. This follows a shelf registration declared effective in March 2020. The funds will support Verrica's dermatology product development, including treatments for skin diseases.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced its intention to offer and sell shares of common stock in an underwritten public offering, subject to market conditions. The offering includes a 30-day option for underwriters to purchase an additional 15% of the shares. Jefferies LLC, Cowen and Company, and RBC Capital Markets are managing the offering. The shares will be sold under a shelf registration statement filed with the SEC. The actual size and terms of the offering are not guaranteed.
Verrica Pharmaceuticals (NASDAQ: VRCA) announced a License Agreement with Torii Pharmaceutical, granting exclusive rights to develop and commercialize its product candidates for molluscum contagiosum and common warts in Japan. Torii will make an upfront payment of $11.5 million and may pay up to $58 million based on milestones. The lead candidate, VP-102, is under FDA review, with a PDUFA goal date of June 23, 2021. The partnership aims to leverage Torii's expertise to address the unmet medical needs of approximately 1.6 million cases of molluscum in Japan.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced the FDA's acceptance of its resubmitted NDA for VP-102, targeting molluscum contagiosum, with a PDUFA goal date of June 23, 2021. The company also revealed that Torii Pharmaceutical will develop and commercialize VP-102 in Japan, with a potential $69.5 million in milestone payments. During Q4 2020, Verrica reported a net loss of $13 million, an increase from $7.6 million in Q4 2019. Full-year 2020 losses reached $42.7 million. Research and development expenses decreased to $2.3 million in Q4 2020. As of December 31, 2020, cash reserves totaled $65.5 million.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Ted White will present a business overview at the H.C. Wainwright Annual Global Life Sciences Conference on March 9-10, 2021. A pre-recorded presentation will be available on-demand starting at 7:00 a.m. ET on March 9, 2021. The event can be accessed via a webcast link provided in the announcement and will also be available on the Verrica website. The company is focused on developing medications for skin diseases, including its late-stage product candidate VP-102, aimed at treating molluscum and warts.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced its participation in the Cowen 41st Annual Health Care Conference on March 2, 2021, at 11:50 a.m. ET, where CEO Ted White will present a business overview. Interested parties can access a live webcast through provided links, with a replay available for 30 days post-event. The company focuses on dermatology therapeutics, developing treatments for conditions like molluscum contagiosum and warts. Its key product candidates include VP-102 and VP-103, with a worldwide licensing agreement for LTX-315.
Verrica Pharmaceuticals announced that its resubmitted New Drug Application (NDA) for VP-102 (0.7% cantharidin topical solution) has been accepted by the FDA, with a PDUFA goal date of June 23, 2021. If approved, VP-102 could be the first FDA-approved treatment for molluscum contagiosum, a viral skin condition affecting around 6 million people in the U.S., mainly children. The NDA is based on positive Phase 3 clinical trial results showing significant clearance of molluscum lesions, with no serious adverse events reported.
Verrica Pharmaceuticals (Nasdaq: VRCA) has announced positive data from post-hoc analyses of its Phase 3 trials for VP-102, a treatment for molluscum contagiosum. Results showed significantly higher clearance rates of lesions across various body regions compared to the vehicle control, starting as early as Day 21. Additionally, in the Phase 2 CARE-1 study for external genital warts (EGW), VP-102 demonstrated a significantly higher clearance rate at Day 63 and Day 84. The FDA is currently reviewing VP-102, which may become the first approved treatment for molluscum contagiosum.
Verrica Pharmaceuticals (Nasdaq: VRCA) has resubmitted the New Drug Application (NDA) for its lead product, VP-102, aimed at treating molluscum contagiosum, a contagious skin disease affecting approximately six million people in the U.S., mainly children. The resubmission responds to a Type A meeting with the FDA and addresses concerns from a previous Complete Response Letter issued in July 2020. If approved, VP-102 will be the first FDA-approved treatment for this condition, marketed as YCANTH™.
Verrica Pharmaceuticals reaffirmed its expectation to resubmit the New Drug Application (NDA) for VP-102, targeting molluscum contagiosum, in Q1 2021. This announcement comes after productive discussions with the FDA addressing prior Chemistry, Manufacturing, and Controls (CMC) issues outlined in a Complete Response Letter received in July. VP-102 is a first-in-class drug-device combination aimed at treating a viral skin disease, currently lacking FDA-approved options. The company is also preparing to complete a Human Factors study by year-end.